Document Detail


The rise in metastasectomy across cancer types over the past decade.
MedLine Citation:
PMID:  25377689     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: Although studies of metastasectomy have been limited primarily to institutional experiences, reports of favorable long-term outcomes have generated increasing interest. In the current study, the authors attempted to define the national practice patterns in metastasectomy for 4 common malignancies with varying responsiveness to systemic therapy.
METHODS: The National (Nationwide) Inpatient Sample was used to estimate the national incidence of metastasectomy for colorectal cancer, lung cancer, breast cancer, and melanoma from 2000 through 2011. Incidence-adjusted rates were determined for liver, lung, brain, small bowel, and adrenal metastasectomies. The average annual percentage change (AAPC) in metastasectomy by cancer type was calculated using joinpoint regression.
RESULTS: Colorectal cancer was the most common indication for metastasectomy (87,407 cases; 95% confidence interval [95% CI], 86,307-88,507 cases) followed by lung cancer (58,245 cases; 95% CI, 57,453-59,036 cases), breast cancer (26,271 cases; 95% CI, 25,672-26,870 cases), and melanoma (20,298 cases; 95% CI, 19,897-20,699 cases). Metastasectomy increased significantly for all cancer types over the study period: colorectal cancer (AAPC, 6.83; 95% CI, 5.7-7.9), lung cancer (AAPC, 5.8; 95% CI, 5.1-6.4), breast cancer (AAPC, 5.5; 95% CI, 3.7-7.3), and melanoma (AAPC, 4.03; 95% CI, 2.1-6.0). Despite an increasing number of comorbidities in patients undergoing metastasectomy (P<.05 for each cancer type), inpatient mortality rates after metastasectomy fell for all cancer types, most significantly for colorectal (AAPC, -5.49; 95% CI, -8.2 to -2.7) and lung (AAPC, -6.2; 95% CI, -11.7 to -0.3) cancers. The increasing performance of metastasectomy was largely driven by high-volume institutions, in which patients had a lower mean number of comorbidities (P<.01 for all cancer types) and lower inpatient mortality (P<.01 for all cancers except melanoma).
CONCLUSIONS: From 2000 through 2011, the performance of metastasectomy increased substantially across common cancer types, notwithstanding various advances in systemic therapies. Metastasectomy was performed more safely, despite increasing patient comorbidity. High-volume institutions appeared to drive practice patterns. Cancer 2014. © 2014 American Cancer Society.
Authors:
Edmund K Bartlett; Kristina D Simmons; Heather Wachtel; Robert E Roses; Douglas L Fraker; Rachel R Kelz; Giorgos C Karakousis
Related Documents :
25415319 - Association of gwas-identified lung cancer susceptibility loci with survival length in ...
18516759 - New combination therapies with cell-cycle agents.
25400589 - Association of cancer history with alzheimer's disease onset and structural brain changes.
17959499 - The circadian timing system, a coordinator of life processes. implications for the rhyt...
25343559 - Pattern of collagen fibers and localization of matrix metalloproteinase 2 and 9 during ...
20976699 - Erbb family receptor inhibitors as therapeutic agents in breast cancer: current status ...
7889489 - Characterization and biodistribution of a mouse/human chimeric antibody directed agains...
22870099 - Type iv collagen levels are elevated in the serum of patients with peritoneal dissemina...
20925499 - Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a la...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-11-6
Journal Detail:
Title:  Cancer     Volume:  -     ISSN:  1097-0142     ISO Abbreviation:  Cancer     Publication Date:  2014 Nov 
Date Detail:
Created Date:  2014-11-7     Completed Date:  -     Revised Date:  2014-11-8    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2014 American Cancer Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Myocardial fat overgrowth in Proteus syndrome.
Next Document:  Nanomedical engineering: shaping future nanomedicines.